You are here: Industry Insights > Galapagos

News List

Galapagos reports early clinical results for SIK inhibitor pharmatimes
July 16, 2021
Galapagos has reported early results from three studies of its salt inducible kinase (SIK) 2/3 inhibitor GLPG3970, the first candidate from its portfolio of SIK inhibitor compounds.
Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation firstwordpharma
July 15, 2021
Galapagos NV(Euronext & Nasdaq: GLPG)reports topline results with GLPG3970 in three patientstudies.
Galapagos’ filgotinib leads to rapid symptom improvement for ulcerative colitis patients pharmatimes
July 13, 2021
A post-hoc analysis from a Phase III clinical programme evaluating Galapagos’ filgotinib showed significant symptom improvements for patients with ulcerative colitis (UC).
Gilead, Galapagos amend commercialisation and development pact for Jyseleca (filgotinib) expresspharma
December 16, 2020
Under the new arrangement, Galapagos will assume sole responsibility in Europe for filgotinib in RA, Gilead to receive royalties on European sales starting in 2024.
Galapagos and Servier report topline results for ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients prnasia
October 16, 2020
Servier and Galapagos NV report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086.
Galapagos signs deal with Scipher for IBD drug development pharmatimes
August 17, 2020
Belgium-based biotech Galapagos has signed a collaboration deal with Scipher Medicine to advance novel drug targets for the treatment of inflammatory bowel disease (IBD).
Gilead and Galapagos announce positive topline results of phase 2b/3 trial of filgotinib in moderate pharmaceutical-business-review
May 27, 2020
Gilead Sciences and Galapagos announced positive topline results from SELECTION, a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the efficacy and safety of the investigational, oral, once-daily ...
Galapagos expands fibrosis research collaboration with Fibrocor pharmaceutical-technology
January 17, 2020
Galapagos has expanded its research collaboration with Candian firm Fibrocor Therapeutics, which develops tissue-specific therapeutics for fibrotic diseases.
Gilead, Galapagos close their development collaboration biospectrumasia
August 26, 2019
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
Gilead and Galapagos deepen R&D alliance with ten-year deal pharmaceutical-technology
July 17, 2019
Gilead Sciences has expanded its partnership with Belgian biotech company Galapagos with a ten-year global research and development (R&D) deal.

Previous page 1 2 3 Next page